scholarly journals Feasibility of using stereotactic body radiation therapy for unresectable soft tissue tumors of the trunk

Oncotarget ◽  
2018 ◽  
Vol 9 (45) ◽  
pp. 27851-27857 ◽  
Author(s):  
Eun Kyung Paik ◽  
Mi-Sook Kim ◽  
Chul-Koo Cho ◽  
Hyung Jun Yoo ◽  
Won Il Jang ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Stereotactic Body Radiation Therapy ◽  
Soft Tissue Tumors ◽  
Stereotactic Body Radiation

Non-surgical Treatments for Lung Metastases in Patients with soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)

2020 ◽  
Vol 16 ◽  
Author(s):  
Cecilia Tetta ◽  
Maria Carpenzano ◽  
Areej Tawfiq J Algargoush ◽  
Marwah Algargoosh ◽  
Francesco Londero ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Disease Free Interval ◽  
Stereotactic Body Radiation ◽  
Free Interval ◽  
Disease Free

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.

Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma

2015 ◽  
Vol 51 (5) ◽  
pp. 668-674 ◽  
Author(s):  
Pierina Navarria ◽  
Anna Maria Ascolese ◽  
Luca Cozzi ◽  
Stefano Tomatis ◽  
Giuseppe Roberto D’Agostino ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Stereotactic Body Radiation

scholarly journals Changes in Volume and Density Parameters Measured on Computed Tomography Images Following Stereotactic Body Radiation Therapy of Nonspine Bone Metastases

2019 ◽  
Vol 18 ◽  
pp. 153303381985353
Author(s):  
Samuel Finkelstein ◽  
Srinivas Raman ◽  
Joanne Van Der Velden ◽  
Liying Zhang ◽  
Carolyn Tan ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Bone Metastases ◽  
Treatment Response ◽  
Local Control ◽  
Stereotactic Body Radiation Therapy ◽  
Bone Lesions ◽  
Stereotactic Body Radiation ◽  
Soft Tissue Volume

Introduction: Volumetric and density parameters measured from computed tomography scans were investigated for evaluating treatment response of nonspine bone lesions following stereotactic body radiation therapy. Methods: Twenty-three patients treated with stereotactic body radiation therapy to nonspine bone metastases with pre- and post-treatment radiological follow-up with computed tomography imaging were identified in a retrospective review. An expert radiologist classified 26 lesions by type (lytic, sclerotic) and by response. Two independent radiation oncologists created separate contours of the bone and soft tissue lesion volumes. Density and volume were assessed relative to baseline values. Results: For bone-only lesions, all lesions designated as local control decreased in volume or remained within 20% of baseline volumes. Lytic lesions classified as progressive disease exhibited much larger volume increases. Lytic bone lesions showed indications of remineralization with some exhibiting immediate increases in density (1-6 months) and others decreasing initially then increasing back toward baseline between 7 and 12 months. The majority of sclerotic lesions, all classified as local control, decreased slightly in both volume and density. Lesions with both soft tissue and boney involvement resulted in contradictory results when employing both radiological and size parameters for assessing treatment response. Classification was dominated by changes in soft tissue volume, despite associated volume or density changes in the corresponding boney lesion. In contrast, when soft tissue volume changes were minimal (<20% increase), classification appeared to be related primarily to density changes and not bone volume. Conclusions: Volume and density changes show promise as quantitative parameters for classifying treatment responses of nonspine osseous lesions. Further work is required for clarifying how these metrics can be applied to lesions with both boney and soft tissue components.

Sign in / Sign up

Export Citation Format

Share Document